Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Keunchil Park, Thomas John, Sang-We Kim, Jong Seok Lee, Catherine A. Shu, Dong-Wan Kim, Santiago Viteri Ramirez, Alexander I. Spira, Joshua K. Sabari, Ji-Youn Han, Jose Manuel Trigo, Chee Khoon Lee, Ki Hyeong Lee, Nicolas Girard, Patricia A Lorenzini, John Xie, Amy Roshak, Meena Thayu, Roland Elmar Knoblauch, Byoung Chul Cho, on behalf of the CHRYSALIS Investigators
Institutions: Samsung Medical Center, Sungkyunkwan University, Austin Health, Asan Medical Center, Seoul National University Bundang Hospital, Columbia University Irving Medical Center, Seoul National University Hospital, Hospital Universitario Dexeus, Virginia Cancer Specialists, New York University, National Cancer Center, Hospital Clínico Universitario Virgen de la Victoria, St George Hospital, Chungbuk National University, Chungbuk National University Hospital, Institut Curie, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Janssen Research and Development
OpenAlex ID: W3030280670
